Methods and use of amphiphilic multi-block co-polymers to block viral infection



    • Viral infections, such that as SARS-CoV-2, cause substantial human morbidity and mortality, and are a significant health burden worldwide.  Most recent epidemiological studies reveal 124 million covid-19 cases globally resulting in 2.73 million recorded deaths. 
    • The inventors demonstrated that attractive hydrophobic interactions between amphiphilic block co-polymers and viral proteins can inhibit viral infection by mediating copolymer adsorption onto the virus and intracellular viral proteins.
    • The invention mechanistic action is modification of the protein folding state of viral proteins with exposed hydrophobic domains (ex. COVID 19).  The modification can disrupt either or both of a) viral entry across a cell membrane or b) the unfolded protein response of newly synthesized viral proteins within an infected cell.
    • Several such co-polymers are already approved for use in humans as adjuvants, and therefore expected to be sage for this broad indication.






    • Viral defense

    • Effective without immune system activation

    • Antigen agnostic



    • Acute intervention to arrest viral-associated complications

    • SARS-CoV-2 viral infection

    • Preclinical in vivo



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager of Market Intelligence, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.